Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.

Exciting new anti-cancer vaccine successfully tested in myeloma patients

Posted on April 11 2012 by Pat Killingsworth | 2,361 views

My inbox was burning-up with emails from readers who had just read about ImMucin, a new anti-cancer vaccine that is expected to work well against a number of different cancers.

It just so happens the first human tests by Israeli researchers were conducted on multiple myeloma patients.  And the results were everything researchers had hoped for!

According to Medical Daily:

“The clinical trial was conducted at the Hadassah Medical Centre in Jerusalem and consisted of ten patients with multiple myeloma, a type of blood cancer that affects plasma cells in bone marrow, have now received the vaccine.

Researchers from the drug maker Vaxil Biotheraputics and Tel Aviv University said that seven of the patients who have finished treatment all had significantly greater immunity against cancer cells compared to before they were given the vaccine, and three of the patients in the study are now free of the condition. “

ImMucin targets a molecule which is present in most cancers.  I first wrote about it in June on my site.  Come on, people.  Weren’t you paying attention?  Here is a link back to the June, 2011 post:

ImMucin currently undergoing a Phase I/II clinical trial for multiple myeloma

A number of different publications  are running stories about ImMucin now.  Preliminary study results haven’t even been published yet.  But the age-old trick of letting news about the study trickle-out ahead of time has really worked this time!  CLICK  HERE to access yesterday’s Medical Daily article that I quoted above.

As it so happens, this is only one of two exciting cancer therapy studies making the news this week.  I will share details about the other one tomorrow.

Feel good and keep smiling!  Pat


6 Comments For This Post

  1. Mike Bird Says:

    What kind of delay can we expect before it becomes freely available? Months…Years…? Thanks, Mike

  2. Pat Killingsworth Says:

    Depends what you mean by “available,” Mike. FDA approved? Try three or four years AT BEST. But, compassionate use provisions could allow the company to dispense the drug–free of charge–to mm salvage therapy patients in less than two years. Also, if it works as well as we are being led to believe (do I sound a bit skeptical?) clinical study opportunities could explode, helping a lot of patients gain access. It’s OK to get excited. But this is a long way from–well–anything! Also, I hate the way these companies have control of what happens and when. (see my posts about perifosine. They might arbitrarily “pull the plug,” even though perifosine looks legit) So an Israeli company? Licensing agreements need to be negotiated. Hopefully they will hook-up with a company with deep, deep pockets!

  3. Ark Says:

    There is a saying in Gujarati language….the literal translation of do that would be like this…..” in light of hundreds of thousands of hopelessness, there is ONE immortal shining hope hidden!!”

    What more should I say to my fellow mm patients.

    Thanks for sharing Pat.


  4. Pat Killingsworth Says:

    Thank you, Abdul! Best of luck to you…

  5. SouthernYankee Says:

    It would be a miracle if this ‘shining hope hidden’ turns out to be the real deal.. If so, I’ll be partying like it’s 1999…Ain’t quite ready to buy the booze just yet though.

  6. Pat Killingsworth Says:

    Hard to argue that the odds say something won’t work quite right in the end… But odds say that one of the three promising new therapies (see tomorrow’s post) should help slow down one or more forms of cancer. Will it be ours? And how long?

1 Trackbacks For This Post

  1. Publication “Fierce Vaccines” warns us not to get too excited about ImMucin | Multiple Myeloma Blog Says:

    […]  Exciting new anti-cancer vaccine successfully tested in myeloma patients […]

Leave a Reply

Follow On Twitter!

Follow HelpWithMyeloma on Twitter